A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission.

Katerina Chatzidionysiou, Carl Turesson, Annika Teleman, Ann Knight, Elisabet Lindqvist, Per Larsson, Lars Cöster, Kristina Forslind, Ronald van Vollenhoven, Mikael Heimbürger

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskriftPeer review

Sammanfattning

Treatment with tumour necrosis factor (TNF) blockers, once started as therapy for rheumatoid arthritis (RA), is usually continued indefinitely. The aim of this trial was to assess the possibility of discontinuing treatment with adalimumab (ADA) while maintaining remission in patients with RA with established disease in stable remission on combination therapy with ADA and methotrexate (MTX).
Originalspråkengelska
Sidor (från-till)e000133
TidskriftRMD Open
Volym2
Nummer1
DOI
StatusPublished - 2016

Ämnesklassifikation (UKÄ)

  • Reumatologi och inflammation

Fingeravtryck

Utforska forskningsämnen för ”A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission.”. Tillsammans bildar de ett unikt fingeravtryck.

Citera det här